Amplia Therapeutics Ltd
ASX:ATX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Porsche Automobil Holding SE
OTC:POAHY
|
DE |
Amplia Therapeutics Ltd
PP&E Net
Amplia Therapeutics Ltd
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Amplia Therapeutics Ltd
ASX:ATX
|
PP&E Net
AU$401.8k
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
PP&E Net
$8.3m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
8%
|
|
|
CSL Ltd
ASX:CSL
|
PP&E Net
$9.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
16%
|
|
|
Race Oncology Ltd
ASX:RAC
|
PP&E Net
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
PP&E Net
AU$115.6m
|
CAGR 3-Years
83%
|
CAGR 5-Years
89%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
PP&E Net
AU$1.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
31%
|
|
Amplia Therapeutics Ltd
Glance View
Amplia Therapeutics Ltd. is a medical biotechnology company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2013-12-23. The Company’s pipeline is developing two orally available small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its initial clinical development pipeline consists of AMP945 and AMP886 (FLT3/VEGFR3). The Company’s cancer program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its Fibrosis Program is the formation of excessive fibrous connective tissues that can result from chronic inflammation, chronic injury or disease. Its FAK inhibitors have been shown to block fibrosis in established animal models of both lung fibrosis and liver fibrosis (NASH).
See Also
What is Amplia Therapeutics Ltd's PP&E Net?
PP&E Net
401.8k
AUD
Based on the financial report for Sep 30, 2025, Amplia Therapeutics Ltd's PP&E Net amounts to 401.8k AUD.
What is Amplia Therapeutics Ltd's PP&E Net growth rate?
PP&E Net CAGR 3Y
20%
Over the last year, the PP&E Net growth was 593%. The average annual PP&E Net growth rates for Amplia Therapeutics Ltd have been 20% over the past three years .
